Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Vanda Pharmaceuticals Inc. VNDA

Healthcare — Biotechnology

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
2.82
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — 1 5 — — — — — —
Insider Ownership
5.03%

Capital & Financial Ratios

Market Cap
304.73
Revenue
215.72
Net Income
(274.85)
Free Cash Flow
(153.00)
Net Debt
(166.85)
Current Ratio
1.61
Debt/Equity
0.01
P/E ratio
0.00
P/S ratio
1.43
P/B ratio
1.40
Past 5Y EPS Growth
(37.98%)
This Y EPS Growth
19.32%
Next Y EPS Growth
65.87%
Next 5Y EPS Growth
54.89%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 388.26 374.64 263.85 170.03
Receivables 34.16 47.10 54.58 59.69
Inventory 1.36 1.73 1.85 1.68
Other — — — —
432.95 438.89 347.26 264.48
2023 2024 2025 Q'26
Payables 38.46 39.09 68.30 69.99
ST’ Debt — — — —
Other 49.24 60.90 76.87 94.03
87.70 99.98 145.16 164.03
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 51.72 50.53 — —
—
’25 50.04 52.59 56.26 57.22
216.11
’24 47.46 50.47 47.65 53.19
198.77
’23 62.50 46.06 38.82 45.27
192.64
’22 60.19 64.39 65.32 64.48
254.38
’21 62.67 67.90 70.10 68.02
268.68
’20 58.00 62.21 60.31 67.65
248.17
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (50.22) (31.07) — —
—
’25 (33.15) (15.25) (31.63) (29.42)
(109.44)
’24 7.57 (6.93) (14.58) (1.82)
(15.76)
’23 31.80 (13.22) (2.05) (3.73)
12.80
’22 4.05 5.69 12.84 9.42
31.98
’21 9.19 19.02 9.40 26.61
64.21
’20 (0.91) 24.01 9.37 19.30
51.78
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (60.44) (31.26) — —
—
’25 (33.58) (15.55) (31.79) (29.52)
(110.44)
’24 4.86 (8.56) (14.74) (2.03)
(20.48)
’23 31.75 (13.27) (2.07) (104.65)
(88.25)
’22 3.97 5.49 12.69 9.15
31.31
’21 9.06 18.72 9.41 26.47
63.66
’20 (1.28) 23.80 9.13 18.34
49.98
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.82) (1.04) — —
—
’25 (0.50) (0.46) (0.38) (2.39)
(3.74)
’24 (0.07) (0.08) (0.09) (0.08)
(0.33)
’23 0.06 0.03 0.00 (0.04)
0.04
’22 (0.11) 0.05 0.06 0.12
0.11
’21 0.15 0.17 0.14 0.12
0.58
’20 0.01 0.16 0.11 0.15
0.42

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1.5
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 6.73 3.30 3.46 3.81 — — —
Low Price
‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 16.93 8.15 6.75 9.60 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 290 203 203 533 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.88 0.95 0.98 0.41 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 254.38 192.64 198.77 216.11 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 90.45% 92.32% 94.31% 93.96% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 11.30 6.34 (22.92) (138.65) ‡‡‡‡‡ — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.44% 3.29% (11.53%) (64.16%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.28 2.51 (18.90) (220.47) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.23) (4.46) 2.81 9.86 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.51 3.36 3.42 3.67 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡ 0.11 0.04 (0.33) (3.74) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.57 0.22 (0.27) (1.86) — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.01) (1.76) (0.08) (0.02) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.55 (1.54) (0.35) (1.87) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 9.34 9.50 9.26 5.55 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 56.46 57.38 58.15 58.93 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 61.83 90.40 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.65 1.35 1.40 2.41 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.79 0.48 0.52 1.59 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.14) (0.62) (0.46) 1.21 ‡‡‡‡ ‡‡‡‡ ‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (5.83) 1.05 1.99 (2.38) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 31.98 12.80 (15.76) (109.44) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.68) (101.05) (4.72) (1.00) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 31.31 (88.25) (20.48) (110.44) ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 427.86 345.25 338.91 202.10 — — —
Working Cap'
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 11.14 — 3.15 4.08 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (455.72) (388.26) (371.50) (259.77) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 527.20 544.91 538.55 327.19 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.02% 0.39% (2.90%) (38.51%) ‡‡‡‡‡ — —
ROA
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.53% (5.57%) (15.21%) (140.15%) — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.22% 0.47% (3.49%) (50.93%) ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Vanda Pharmaceuticals (VNDA), a CNS-focused biopharma, trades near multi-year lows around $5, reflecting investor doubts over near-term losses from R&D and clinical setbacks, despite a rock-solid balance sheet with $371 million in net cash and minimal debt. Revenue grew robustly from $146 million in 2016 to a $269 million peak in 2021, dipped on Hetlioz generics, but rebounded modestly to $199 million in 2024 with improving gross margins near 94%. Lean operations shine through, with revenue per employee at $900K-$1M even after staff cuts, positioning VNDA for explosive growth.

Analysts forecast revenue surging 9% to $216 million in 2025, then 19%-36% annually through 2028 to $419 million, fueled by pipeline stars like Phase 3 tradipitant for gastroparesis and motion sickness. Profitability has swung wildly—EPS windfalls from milestones like 2019’s $120M Vraylar payment to recent losses—but projections signal a 2026 turnaround with positive FCF. Valuation screams bargain: PS at 1.4x, PB at 0.52x, and mean analyst targets implying 105% upside (high of 260%).

Aggressive CEO insider buying—over $317K for 70K shares at $4.50-$5—adds conviction amid oversold conditions, echoing past rebounds from Hetlioz launches. While clinical risks linger, VNDA’s metrics suggest asymmetric upside if catalysts hit. Dive into the full analysis for revenue-profit correlations, cash flow details, and key events driving this undervalued gem.

Read full commentary →

Vanda Pharmaceuticals Inc. (VNDA) Latest News

News by impact score

Fine-tune

24 Aug

3 , 7:00 AM
Vanda Pharmaceuticals received orphan designation from the European Commission for imsidolimab to treat generalized pustular psoriasis. Orphan designation provides market exclusivity and regulatory incentives that support imsidolimab development in a rare disease indication.

12 Aug

3 transcript www.fool.com, 7:13 PM
Vanda Pharmaceuticals Inc. (VNDA) conducted its Q2 2026 earnings call. Q2 2026 earnings call delivers financial results and outlook that influence near-term market views.

6 Aug

3 transcript www.marketbeat.com, 3:03 AM
Vanda Pharmaceuticals Inc. (VNDA) held its Q2 earnings call, covering financial results, operational updates, and business outlook. Q2 earnings details and guidance can moderately shift investor views and near-term stock movement.

5 Aug

3 transcript app.moby.co, 11:30 PM
Vanda Pharmaceuticals Inc. held its Q2 2026 earnings call covering financial results, operational updates, and forward guidance. Quarterly earnings call supplies updated financial metrics and outlook that can move near-term sentiment but rarely reshapes long-term trajectory.

3 , 5:10 PM
Vanda Pharmaceuticals reported a Q2 loss and missed revenue estimates. Q2 loss and revenue shortfall can pressure near-term stock price and sentiment.

16 Jul

4 , 4:30 PM
Vanda Pharmaceuticals receives EMA positive opinion granting orphan drug designation to Imsidolimab for generalized pustular psoriasis, recognizing GPP as a distinct rare disease in Europe. EMA orphan designation advances Imsidolimab with regulatory incentives and market exclusivity that can materially boost Vanda pipeline value and investor sentiment.

7 Jul

4 stocktwits.com, 8:22 PM
VNDA stock gains after-hours as FDA grants rare pediatric disease designation for experimental therapy. FDA rare pediatric disease designation advances therapy development and enhances market position for Vanda Pharmaceuticals.

3 , 4:30 PM
Vanda Pharmaceuticals received FDA Rare Pediatric Disease Designation for its investigational therapy targeting Charcot-Marie-Tooth Disease Type 2S. FDA designation for an early-stage investigational therapy provides regulatory benefits but does not immediately alter company operations or financials.

27 May

3 PR Newswire, 7:00 AM
Vanda Pharmaceuticals secured orphan drug designation in Japan for imsidolimab in generalized pustular psoriasis. Orphan drug designation in Japan supports imsidolimab development for a rare condition but represents a limited regulatory milestone without immediate revenue impact.

17 May

4 Simply Wall St., 11:14 PM
Vanda Pharmaceuticals investment narrative evolves amid BYSANTI and Nereus developments that reshape company prospects. BYSANTI and Nereus mark strategic product shifts that can materially change VNDA trajectory and investor sentiment.

7 May

3 www.marketbeat.com, 4:18 AM
Vanda Pharmaceuticals Inc. (VNDA) released Q1 earnings call highlights detailing financial results, pipeline updates, and forward guidance. Q1 earnings highlights address financial performance and operational updates with moderately noticeable influence on investor sentiment and stock trajectory.

6 May

4 app.moby.co, 8:26 PM
Vanda Pharmaceuticals Inc. (VNDA) Q1 2026 earnings call summary covers quarterly financial results, operational updates, pipeline progress, and forward guidance. Q1 2026 earnings disclosure includes financial metrics and strategic outlook directly shaping VNDA's market valuation and investor confidence.

4 transcript www.fool.com, 6:28 PM
Vanda Pharmaceuticals (VNDA) Q1 2026 earnings call transcript covers first-quarter financial results, product updates, pipeline progress, and management guidance on future operations. Q1 2026 earnings transcript details financial performance and strategic outlook, likely driving significant shifts in investor sentiment and stock trajectory.

4 PR Newswire, 4:01 PM
Vanda Pharmaceuticals Inc. (VNDA) reported first quarter 2026 financial results. Quarterly financial results directly shape investor sentiment, stock valuation, and future performance expectations.

3 Zacks, 5:10 PM
Vanda Pharmaceuticals Inc. (VNDA) reported a first-quarter net loss with total revenues missing analyst estimates. Q1 loss and revenue miss highlight financial underperformance, moderately impacting investor sentiment and near-term stock performance.

5 May

4 Zacks, 9:55 AM
Wall Street analysts predict a 105.03% upside for Vanda Pharmaceuticals Inc. (VNDA) stock. Analysts' 105.03% upside forecast signals major positive shift in investor sentiment and VNDA's market trajectory.

4 May

4 PR Newswire, 8:00 AM
Vanda Pharmaceuticals Inc. announces U.S. commercial availability of NEREUS™ (tradipitant), the first new pharmacologic treatment for motion sickness in more than 40 years. Launching the first new motion sickness drug in over 40 years provides Vanda with a major revenue opportunity and strengthens its product pipeline.

1 May

4 PR Newswire, 4:30 PM
Vanda Pharmaceuticals Inc. (VNDA) announces U.S. commercial availability of NEREUS™ (tradipitant), the first new pharmacologic treatment for motion sickness in more than 40 years. Commercial launch of the first new motion sickness drug in over 40 years provides VNDA with a significant new revenue opportunity and strengthens its product portfolio.

28 Apr

4 , 7:12 PM
Vanda Pharmaceuticals Inc. (VNDA) announced publication of the study 'Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis' in NEJM Evidence. Publication of positive clinical data for Imsidolimab in a prestigious journal like NEJM Evidence represents a major milestone boosting VNDA's drug pipeline and investor confidence.

9 Apr

4 PR Newswire, 11:02 AM
Vanda Pharmaceuticals Inc. (VNDA) calls on the FDA to withdraw a proposal from its FY 2027 legislative agenda that would extend drug review timelines. Regulatory proposal to extend drug review timelines threatens VNDA's approval processes and pipeline timelines, with company's opposition highlighting significant potential impact on future performance.

8 Apr

3 PR Newswire, 4:30 PM
Vanda Pharmaceuticals Inc. (VNDA) announces initiation of The Thetis Study, a clinical trial evaluating NEREUS™ for preventing vomiting induced by GLP-1 receptor agonists. Initiation of The Thetis Study positions NEREUS™ to address a common side effect of blockbuster GLP-1 drugs, offering moderate potential for product innovation and market expansion.

13 Mar

4 Simply Wall St., 8:08 AM
Vanda Pharmaceuticals (VNDA) stock jumped 17.4% after FDA granted rare public hearing on HETLIOZ for jet lag treatment, a key step toward potential label expansion. Rare FDA hearing grant for HETLIOZ jet lag indication signals major regulatory progress with high potential to expand market and boost VNDA performance.

3 Mar

4 PR Newswire, 8:00 AM
Vanda Pharmaceuticals announces FDA granted a landmark hearing for HETLIOZ in Jet Lag Disorder, the first drug approval hearing in over 40 years. FDA's landmark hearing for HETLIOZ in jet lag disorder signals major regulatory progress that could expand VNDA's market and revenue significantly.

25 Feb

4 PR Newswire, 7:18 AM
Vanda Pharmaceuticals Inc. (VNDA) announces FDA acceptance of its Biologics License Application filing for Imsidolimab to treat Generalized Pustular Psoriasis. FDA BLA acceptance for Imsidolimab advances a potential new treatment for Generalized Pustular Psoriasis, significantly bolstering VNDA's pipeline and investor outlook.

20 Feb

5 Investing.comMarketBeat, 9:22 PM
Vanda Pharmaceuticals Inc. (VNDA) stock surged after FDA approval of its new drug for Bipolar I disorder. FDA approval of a novel Bipolar I drug represents a game-changing regulatory milestone that transforms VNDA's revenue prospects and competitive position.

5 PR Newswire, 5:59 PM
Vanda Pharmaceuticals Inc. (VNDA) announces FDA approval of BYSANTI™ (milsaperidone) for treating Bipolar I Disorder and Schizophrenia, a new chemical entity advancing psychiatric innovation. FDA approval of a novel drug for major psychiatric disorders provides transformative revenue potential and expands VNDA's market position.

12 Feb

3 transcript app.moby.co, 8:08 PM
Vanda Pharmaceuticals Inc. reported its Q4 2025 earnings, highlighting key financial metrics and operational updates. The company experienced fluctuations in revenue and discussed ongoing clinical trials for its product pipeline. Management provided insights into strategic initiatives aimed at enhancing market presence and addressing competitive challenges. Future outlook and guidance were also shared, indicating potential growth areas and anticipated hurdles. Moderate influence expected due to financial performance and strategic initiatives that may affect the company's trajectory.

3 GuruFocus.com, 12:02 AM
Vanda Pharmaceuticals Inc. reported its Q4 2025 earnings, showcasing revenue growth despite an increase in losses. The company highlighted key developments in its product pipeline and strategic initiatives aimed at enhancing market presence. However, rising operational costs and competitive pressures raised concerns about long-term profitability. Investors are closely monitoring these trends as Vanda navigates its financial challenges while striving for sustainable growth. Revenue growth amid rising losses indicates a need for strategic adjustments to ensure long-term viability.

11 Feb

3 transcript www.fool.com, 6:21 PM
Vanda Pharmaceuticals Inc. reported its Q4 2025 earnings, highlighting key financial metrics and operational updates. The company discussed its ongoing product developments and market strategies, emphasizing growth in specific therapeutic areas. Management provided insights into future expectations and potential challenges, while addressing investor questions regarding performance and strategic direction. Moderate influence on financial performance and strategic positioning is expected due to ongoing product developments and market strategies.

3 transcript www.marketbeat.com, 6:02 PM
Vanda Pharmaceuticals Inc. reported its Q4 earnings, highlighting key financial metrics and strategic initiatives. The company discussed its performance, including revenue figures and product developments, while addressing market challenges and future outlook. Management provided insights into ongoing projects and potential growth areas, emphasizing their commitment to innovation and patient care. The earnings call revealed important financial performance details and strategic initiatives that may moderately influence the company's future trajectory.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us